Calimmune Overview

  • Founded

  • 2006

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 40

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $416M

Calimmune General Information

Description

Developer of a gene modification and cell delivery technology designed to translate the promise of gene therapy into effective and accessible products that have the power to restore health and improve lives. The company's gene modification and cell delivery technology works by genetically modifying patients' own cells to shield and strengthen their immune system and create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases, enabling physicians to address the unique needs of individuals at different stages of HIV infection and with various treatment histories.

Contact Information

Website
www.calimmune.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
CSL
Primary Office
  • 5151 East Broadway Boulevard
  • Suite 1020
  • Tucson, AZ 85711
  • United States
+1 (310) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 11-Sep-2017 $416M 000.00 00000 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 27-May-2015 000.00 000.00 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 01-Dec-2013 000 00.000 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC 16-Sep-2011 000 00.000 Completed Generating Revenue
2. Angel (individual) 01-Jun-2010 $50K $50K Completed Startup
1. Grant $8.28M Completed Startup
To view Calimmune’s complete valuation and funding history, request access »

Calimmune Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 0,000,000 00.000000 00 000.0 000.0 00 000.0 0.000
Series A 0,000,000 00.000000 00 000.0 000.0 00 000 00.000
Series 4 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 3 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 2 107,000 $0.001000 8% $4.94 $4.94 1x $4.94 0.85%
Series 1 188,136 $0.001000 8% $5 $5 1x $5 1.49%
To view Calimmune’s complete cap table history, request access »

Calimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene modification and cell delivery technology designed to translate the promise of gene therapy into eff
Biotechnology
Tucson, AZ
40 As of 2015
000.00
0000 0000-00-00
000000&0 000.00

000000

g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000 000000000
Cambridge, United Kingdom
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

000000

lum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proid
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Calimmune Competitors (86)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DefiniGEN Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
00000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
00000 000000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000 000 Formerly VC-backed South San Francisco, CA 000 00000 000000000 00000
You’re viewing 5 of 86 competitors. Get the full list »

Calimmune Executive Team (14)

Name Title Board Seat Contact Info
James Sullivan Ph.D Director
Inder Verma Ph.D Co-Founder & Scientific Advisor
Irvin Chen Ph.D Co-Founder & Scientific Advisor
Jon Faiz Kayyem Ph.D Board Member and Co-Founder
Margo Lunsford JD Vice President, Business Technology
You’re viewing 5 of 14 executive team members. Get the full list »

Calimmune Board Members (8)

Name Representing Role Since
David Baltimore Ph.D Self Co-Founder & Co-Chairman 000 0000
Harry George III Self Board Member 000 0000
Jon Faiz Kayyem Ph.D Calimmune Board Member and Co-Founder 000 0000
Scott Greer Self Co-Chairman 000 0000
You’re viewing 4 of 8 board members. Get the full list »

Calimmune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calimmune Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
DVI Equity Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial